Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Everolimus in Refractory Metastatic Renal Cell Carcinoma
NCT00651482Phase 2Terminated
- Start
- Aug 2008
- Primary completion
- Mar 2012
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and everolimus in renal cell carcinoma (RCC). Primary endpoint: Progression-free Survival at 24 months. Started Aug 2008; status: terminated.
02
Drugs
bevacizumabeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00651482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651482.